Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | FDPS | P14324 | 9/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15578250 | 1.00 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL26033082 | 0.91 | LMNA (0.30) | LMNA | |
| SCHEMBL24008653 | 0.83 | TSHR (0.33) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL4655855 | 0.83 | OPRM1 (0.38) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL14778336 | 0.82 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL14776743 | 0.82 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL14778522 | 0.82 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL14778513 | 0.82 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL18506048 | 0.82 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 | |
| SCHEMBL14778294 | 0.82 | LMNA (0.36) | LMNATSHRTHRBGGPS1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944634-B2 | Pyrazolopyridine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20180002310-A1 | CRYSTALLINE FORMS OF EFINACONAZOLE | PERRIGO API LTD. (IL) | 2018-01-04 | — | — | US | disclosed |
| EP-2914597-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-20170190695-A1 | PARASITE- AND HYGIENIC PEST-CONTROLLING AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9637480-B2 | Parasite- and hygienic pest-controlling agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| EP-2583964-B1 | NEW CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO PHARMACEUTICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-4665065-A | 3-pyrazolo(1,5-aαpyridinium cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0063359-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0164113-A2 | 3-pyrazolo(1,5-a)pyridinium cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0160252-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-11-06 | — | — | EP | disclosed |
| EP-0101023-A1 | Process for preparing 2-carbamoyloxyalkyl-1,4-dihydropyridine derivatives and intermediates useful for the process | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1984-02-22 | — | — | EP | disclosed |
| EP-0063359-A1 | 1,4-Dihydropyridine derivatives and processes for preparing the same | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1982-10-27 | — | — | EP | disclosed |
| EP-0000322-B1 | COMPOUNDS HAVING AN ANTI-DEPRESSIVE OR TRANQUILIZING ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | Astra Läkemedel Aktiebolag (SE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0028682-A2 | Intermediates useful at the preparation of compounds having anti-depressive or tranquilizing activity | Astra Läkemedel Aktiebolag (SE) | 1981-05-20 | — | — | EP | disclosed |
| EP-0000322-A1 | Compounds having an anti-depressive or tranquilizing activity, pharmaceutical compositions containing them, and processes and intermediates for their preparation | Astra Läkemedel Aktiebolag (SE) | 1979-01-10 | — | — | EP | disclosed |
| US-4080469-A | INSECTICIDES, MITICIDES | UNION CARBIDE CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002310-A1 | CRYSTALLINE FORMS OF EFINACONAZOLE | CYP3A43, CYP4F3, CYP2F1 | LMNA 2471/4885TSHR 4736/4885THRB 4823/4885 |
| US-20170190695-A1 | PARASITE- AND HYGIENIC PEST-CONTROLLING AGENT | H1-3, H1-2, H1-0 | LMNA 3380/4885TSHR 1004/4885THRB 2287/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LMNA 2945/4885TSHR 3427/4885THRB 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.